MEDICAMEQ — Medicamen Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Medicamen Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,127	1,154	1,409	1,793	1,625
Cost of Revenue
Gross Profit	351	499	549	698	779
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	959	976	1,232	1,640	1,558
Operating Profit	168	179	176	153	67.9
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	164	181	170	131	98.8
Provision for Income Taxes
Net Income After Taxes	121	149	147	94.9	65.6
Minority Interest
Net Income Before Extraordinary Items
Net Income	121	149	148	109	71.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	121	149	148	109	71.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	9.93	12.2	11.9	8.68	5.59
Dividends per Share